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ABSTRACT
Chronic exposure to inorganic arsenic (iAs) has been linked to an increased risk of diabetes, yet the specific disease
phenotype and underlying mechanisms are poorly understood. In the present study we set out to identify iAs exposure-
associated metabolites with altered abundance in nondiabetic and diabetic individuals in an effort to understand the
relationship between exposure, metabolomic response, and disease status. A nested study design was used to profile
metabolomic shifts in urine and plasma collected from 90 diabetic and 86 nondiabetic individuals matched for varying
iAs concentrations in drinking water, body mass index, age, and sex. Diabetes diagnosis was based on measures of
fasting plasma glucose and 2-h blood glucose. Multivariable models were used to identify metabolites with altered
abundance associated with iAs exposure among diabetic and nondiabetic individuals. A total of 132 metabolites were
identified to shift in urine or plasma in response to iAs exposure characterized by the sum of iAs metabolites in urine
(U-tAs). Although many metabolites were altered in both diabetic and nondiabetic 35 subjects, diabetic individuals
displayed a unique response to iAs exposure with 59 altered metabolites including those that play a role in tricarboxylic
acid cycle and amino acid metabolism. Taken together, these data highlight the broad impact of iAs exposure on the
human metabolome, and demonstrate some specificity of the metabolomic response between diabetic and nondiabetic
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individuals. These data may provide novel insights into the mechanisms and phenotype of diabetes associated with iAs
exposure.
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Drinking water contaminated with inorganic arsenic (iAs) is a
major threat to human health with more than 100 million peo-
ple worldwide exposed to levels that exceed the World Health
Organization’s (WHO) recommended limit of 10 lg As/L (WHO,
1993). Chronic exposure to iAs has been linked to an increased
risk of cancer and noncancerous diseases, including cardiovas-
cular disease and diabetes mellitus (Kuo et al., 2013; Maull et al.,
2012; Moon et al., 2012; Navas-Acien et al., 2006; States et al.,
2009). Although many of the original reports refer to iAs-associ-
ated diabetes simply as Type-2 diabetes, growing evidence sug-
gests that the disease phenotype and mechanisms of iAs-
associated diabetes are more complex. Type-2 diabetes is often
associated with obesity and is characterized primarily by hyper-
insulinemia, insulin resistance with a compensatory increase in
insulin secretion, followed by b-cell dysfunction (Adams, 2011).
However, a recent study from areas with low to moderate con-
centrations of iAs in drinking water found positive association
between iAs and diabetes yet negative correlations between iAs
exposure and indicators of insulin resistance (i.e. fasting plasma
insulin and homeostatic model assessment of insulin resist-
ance (HOMA-IR)) (Del Razo et al., 2011; Navas-Acien, 2012).
Similarly, mice that developed diabetes as a result of chronic
exposure to iAs in drinking water exhibited a phenotype charac-
terized by a lack of insulin resistance and an impaired response
of b-cells to glucose challenge (Paul et al., 2011). Taken together
these studies highlight that iAs-associated diabetes is poten-
tially mechanistically different from Type 2 diabetes.
Laboratory studies using tissue culture systems have shown
that arsenite (iAsIII) and its trivalent methylated metabolites
inhibit insulin signaling and insulin-dependent glucose uptake
in a Type-2 diabetes manner (Paul et al., 2007). However, these
arsenicals are also potent inhibitors of glucose-stimulated insu-
lin secretion by pancreatic b-cells or isolated pancreatic islets
(Douillet et al., 2013; Fu et al., 2010). Thus, the results of both
population and laboratory studies of iAs-associated diabetes are
not consistent with the typical Type 2 diabetes phenotype.
These studies point instead to pancreatic b-cells as the primary
target for iAs exposure and to b-cell dysfunction as the primary
mechanism as opposed to insulin resistance. Understanding
the phenotype of iAs-associated diabetes and mechanisms
underlying this disease is essential for the development of
effective treatment strategies in areas where drinking water is
contaminated with iAs.
The north-eastern region of Mexico, Chihuahua, is an area
with high concentrations of iAs in surface and underground
water reservoirs. The concentrations of iAs in Chihuahua drink-
ing water supplies have historically reached up to 800 mg/l (CNA,
2002). During recent years, a limited number of low-capacity
purification systems have been installed in rural towns and vil-
lages, providing local residents with sources of clean water as
an alternative to the contaminated water still supplied through
the most municipal water networks. However, because of the
cost of maintaining these purification systems and a limited
accessibility, tens of thousands of Chihuahua residents con-
tinue using water with unsafe levels of iAs.
To examine the association between iAs exposure and dia-
betes in this area and to better characterize the phenotype of
iAs-associated diabetes, we recently established a cohort of
1165 Chihuahua residents exposed to a wide range of iAs con-
centrations. All subjects in the cohort underwent medical
exams focusing on diabetes and were assessed for iAs exposure
in both urine and drinking water. The present study used a
nested subcohort of 176 individuals, including both diabetic and
nondiabetic individuals, to characterize urine and plasma
metabolomes associated with iAs exposure. In the context of
disease, a primary goal of this research was to identify both
“shared” metabolites, i.e. metabolites that are associated with
iAs exposure in either diabetic or nondiabetic individuals, as
well as diabetes-unique metabolites that can help to character-
ize iAs-associated diabetes.
MATERIALS AND METHODS
The Chihuahua cohort. All procedures involving human subjects
were approved by the IRBs of UNC Chapel Hill and Cinvestav-
IPN, and all participants signed a written consent. A total of
1165 adults (18 years old) with a minimum of 5-year uninter-
rupted residency in the study area were recruited between 2008
and 2012 (Currier et al., 2014). Pregnant women and subjects
reporting kidney or urinary tract infection were excluded
because these conditions may affect profiles of iAs metabolites
in urine. Individuals with potential occupational exposure to
iAs (e.g. those working with pesticides or in mines or smelters)
were also excluded. Samples of drinking water were obtained
from each subjects’ households. An interviewer-administered
study questionnaire was used to record data on residency, occu-
pation, drinking water sources and use, smoking, alcohol con-
sumption, and medical history. Spot urine and fasting venous
blood were collected during medical exams which included an
oral glucose tolerance test with blood drawn 2 h after a 75 g glu-
cose dose. Plasma from both fasting and 2-h blood samples and
urines were immediately frozen and stored at 80C. Measures
of body weight and height were obtained during the exams and
used to calculate body mass index (BMI).
The nested subcohort. The following criteria and methods were
used to select individuals for this subcohort: For the purpose of
this study, only individuals with either fasting plasma glucose
(FPG) 126 mg/dl or two hour blood glucose (2HPG) 200 mg/dl
were considered diabetic. Individuals who reported previous
diabetes diagnosis or use of diabetic medication but with both
FPG< 126 mg/dl and 2HPG< 200 mg/dl were not treated as dia-
betic individuals. Using these criteria, 90 diabetic individuals
were identified. For comparison, 90 nondiabetic individuals
were randomly selected from the cohort within strata of iAs
concentration in drinking water (<10, 10–49, 50–149, 150 mg As/
L), BMI (<25, 25–29, 30), sex and age (39, 40–49, 50–59, 60) to
match the distribution of these factors among the cases.
The matching criteria were relaxed in four instances when
there were no nondiabetic individuals in the same stratum as
the case. In addition, four nondiabetic subjects were subse-
quently excluded from the study because of incorrect or missing
data on iAs in water, BMI, or use of diabetic medication. Thus,
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the final number of subjects included in the nested subcohort
were 90 diabetic and 86 nondiabetic individuals.
Measures of iAs exposure. Hydride generation-atomic absorption
spectrometry coupled with a cryotrap (HG-CT-AAS) was used to
determine the concentration of iAs in drinking water (DW-iAs)
and concentrations of As species in urine, including total iAs,
total monomethyl-As (MAs), and total dimethyl-As (DMAs)
(Hernandez-Zavala et al., 2008). For quality control, a certified
standard reference material Arsenic Species in Frozen Human
Urine (SRM 2669; National Institute of Standards and
Technology) was analyzed with every single batch of urine sam-
ples shipped from the field to UNC. The concentrations of As
species measured by HG-CT-AAS in SRM 2669 ranged from
86.7% to 106.4% of the certified values. The limit of detection
(LOD) for As in water was 0.1 mg As/L; LODs for As species in
urine were 0.05 ng As/ml for MAs or DMAs and 0.1 ng As/ml for
iAs. The concentration of total speciated As in urine (U-tAs) was
calculated as sum of iAs, MAs, and DMAs. Creatinine concentra-
tion in urine was determined by a colorimetric assay (Cayman
Chemical Company, Ann Arbor, MI).
Glucose analysis. FPG and 2HPG levels were measured using a
Prestige 24i Chemistry Analyzer (Tokyo Boeki, Tokyo, Japan). To
ensure accuracy, the analyzer was calibrated prior to analysis
and reference human sera with normal and elevated glucose
levels (Serodos and Serodos PLUS, Human Diagnostics
Worldwide) were used for quality control.
Metabolomic data acquisition. Metabolic profiling was carried out
in plasma and urine using gas chromatography (GC) and liquid
chromatography (LC) with time of flight-mass spectrometry
(TOF-MS) detection (Qi et al., 2007, 2009, 2012; Xie et al., 2008).
Here, the GC-TOF-MS spectra were obtained with electron
impact ionization (70 eV) at full scan mode (m/z 40–600) with a
Rxi-5 ms capillary column (30 m 250 mm i.d., 0.25-mm film
thickness, Restek, PA) on a Pegasus HT system (Leco Co, St
Joseph, MI) coupled with an Agilent 6890 GC (Agilent Co, Santa
Clara, CA), using helium as the carrier gas at a constant flow
rate of 1.0 ml/min. The acquired data files were analyzed by
ChromaTOF software (Leco Co). The LC-TOF-MS mass spectra
were obtained with Thean Agilent HPLC 1200 system coupled
with 6220 MSD TOF-mass spectrometer (MS) (Agilent
Corporation Co, Santa Clara, CA). The acquired GC-TOF-MS and
LC-TOF-MS data were processed using ChromaTOF software
(Leco Co), Agilent MassHunter Qualitative Analysis Program
(vB.05.00), and XCMS package (v1.24.1, http://metlin.scripps.edu)
(Cheng et al., 2012; Xie et al., 2013). Spectral data conversion was
performed using the Agilent MassHunter Qualitative Analysis
Program (vB.05.00) and XCMS package. Metabolites were verified
and annotated using an in-house library of>800 mammalian
metabolites and the online databases, including the Human
Metabolome Database (http://www.hmdb.ca/), the National
Institute of Standards and Technology library, and the LECO/
Fiehn Metabolomics Library. Relative amounts of the metabo-
lites (individual metabolite peak area divided by the sum of all
metabolite peak areas) were used in statistical analyses.
Statistical analyses. Data were analyzed using the statistical
packages SAS 9.3 (SAS Institute Inc, Cary, NC) and Partek
VR
Genomics SuiteTM Software (St Louis, MO). A Spearman rank
test was used to quantify the relationship between DW-iAs and
U-tAs (Supplementary Fig. 1). Descriptive statistics were used to
summarize iAs in drinking water, U-tAs, and other demographic
factors. Because specific gravity was found to be associated
with diabetes status within this cohort (Currier et al., 2014) and
urinary creatinine levels have been previously linked with iAs
exposure, unadjusted values of U-tAs were used in the primary
model in the analyses (Basu et al., 2011; Gamble and Liu, 2005;
Yassine et al., 2012). The abundance levels of the 221 plasma
metabolites and 294 urine metabolites were used for analyses.
Human Metabolome Database Identifiers (HMDB IDs) were also
determined for metabolites to facilitate comparison between
other studies.
The GC-TOF-MS and LC-TOF-MS analyses identified 294 uri-
nary and 221 plasma metabolites, including 89 metabolites that
were detected in both plasma and urine with a total of 426
unique metabolites that were profiled in this study
(Supplementary Tables 1 and 2). Multivariable regression mod-
els were used to establish relationships between metabolite lev-
els and iAs exposure in diabetic and nondiabetic individuals,
where U-tAs was used as the main predictor variable and
metabolite levels the dependent variable. BMI, age, and sex
were selected as covariates based on a priori association with
diabetes. Statistical significance was set at p< .05.
Pathway analysis of statistically significant metabolites. Associations
of statistically significantly metabolites with canonical meta-
bolic pathways were determined using the MetPA tool within
Metabolomics Pathway Analysis (Xia and Wishart, 2010). This
tool maps metabolites onto KEGG pathways and determines the
statistical significance as well as the impact of metabolite
groups. Human Metabolome Database (HMDB) identifiers were
used for these analyses as they provided greater coverage of
metabolites than did the metabolite names (Xia and Wishart,
2010). As the metabolites had already been statistically filtered,
a more lax statistical significance of p< .1 was used in the path-
ways analysis.
RESULTS
Basic Characteristics of the Subcohort
The subcohort selected for the present study (n¼ 176) consisted
of 133 (75.6%) women and 43 (24.4%) men (Table 1). Men and
women were equally represented in the diabetic and
nondiabetic groups (Table 1). There were no statistically signifi-
cant differences on average between the two groups for BMI,
age, drinking water iAs or U-tAs (Table 1). Among the 176 indi-
viduals, a total of 152 (86.9%) individuals were exposed to DW-
iAs levels exceeding 25 mg As/l, the current maximum allowable
contaminant value for iAs for drinking water supplies in
Mexico. Only 20 water samples (11.3%) had DW-iAs below the
WHO recommended value of 10 mg As/L. DW-iAs was signifi-
cantly correlated with U-tAs: r¼ 0.37, p< .01 (Supplementary
Fig. 1). The key characteristics of the entire Chihuahua cohort
were described elsewhere (Currier et al., 2014).
Basic Characteristics of the Metabolome
Of the 426 unique metabolites measured, a total of 132 metabo-
lites were significantly increased or decreased with exposure to
iAs (characterized by U-tAs) among either diabetic or
nondiabetic individuals (Supplementary Table 1). Of these, 103
were urinary and 32 were plasma metabolites (Table 2), with
three metabolites common to both urine and plasma
(Supplementary Table 1). However, the response to iAs exposure
differed between the matrices. Although in urine the
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concentrations for most of the altered metabolites (n¼ 68, 66%)
increased, the concentrations of most of the plasma metabolites
(n¼ 20, 63%) decreased (Table 2, Supplementary Table 1).
Urinary and Plasma Metabolites Associated with U-tAs
in Nondiabetic and Diabetic Subjects
In urine, a total of 61 metabolites were associated with U-tAs
among nondiabetic subjects and 73 metabolites were associated
with U-tAs among diabetic subjects (Fig. 1a, Table 2,
Supplementary Table 1). Of those metabolites, 30 were unique
to nondiabetic individuals, 42 were unique to diabetic individu-
als, and 31 metabolites were associated with U-tAs in both
groups (Fig. 1a). Among the 31 common metabolites were
those related to amino acid metabolism, the tricarboxylic acid
(TCA) cycle, and pyruvate metabolism. The majority of the uri-
nary metabolites showed a positive association with iAs expo-
sure: 35 of the 61 metabolites in nondiabetics, and 52 of the 73
metabolites in diabetic individuals (Table 2, Supplementary
Table 1).
In plasma, a total of 15 metabolites were associated with U-
tAs among nondiabetic individuals and 17 metabolites were
associated with U-tAs among diabetic individuals (Fig. 1b,
Supplementary Table 1). No U-tAs-associated metabolites in
plasma were common among the diabetic and nondiabetic sub-
jects (Fig. 1b, Supplementary Table 1). Many of the plasma
metabolites were negatively associated with iAs exposure: 8 of
the 17 metabolites in diabetics and 12 of the 15 metabolites in
nondiabetic individuals (Table 2, Supplementary Table 1). Thus,
across the two matrices diabetic individuals displayed altered
levels of 59 metabolites (42 urinary metabolites and 17 plasma
metabolites) (Supplementary Table 1).
Urinary and Plasma Metabolite-Enriched Pathways in
Nondiabetic and Diabetic Subjects
Using METPA to perform KEGG enrichment analysis, the 61 uri-
nary metabolites associated with U-tAs in nondiabetic individu-
als were enriched for 9 metabolic pathways (Fig. 1c, Table 3).
Three of these pathways were associated with amino acid
metabolism (alanine/aspartate/glutamate, phenylalanine, argi-
nine and proline), 5 with carbohydrate/energy metabolism (TCA
cycle, glyoxylate/dicarboxylate, galactose, pentose/glucuronate,
and pyruvate), and 1 was associated with vitamin (riboflavin)
metabolism (Table 3).
The 73 urinary metabolites identified in diabetic individuals
enriched for 8 pathways (Fig. 1c, Table 3). Of these pathways, 3
were associated with amino acid metabolism (alanine/aspar-
tate/glutamate, phenylalanine, taurine) and 4 with carbohy-
drate/energy metabolism (TCA cycle, glyoxylate, pentose, and
pyruvate). One pathway was associated with nucleic acid
(purine) metabolism (Table 3).
When examining the overlap between the study groups at a
pathway level, there were 6 pathways that were associated with
U-tAs in both nondiabetic and diabetic subjects. These were path-
ways for metabolism of alanine/aspartate/glutamate, glyoxylate/
dicarboxylate, pentose/glucuronate, phenylalanine, and pyru-
vate, and TCA cycle (Fig. 1c, Table 3). Three pathways were
unique to the metabolome of nondiabetic subjects, including the
pathways of arganine/proline, galactose, and riboflavin metabo-
lism. Two pathways involved in purine and taurine metabolism
were unique to the metabolome of diabetic subjects.
When KEGG enrichment analysis was conducted for the 15
plasma metabolites associated with U-tAs in nondiabetic
TABLE 1. Basic Characteristics of the Subcohort
Entire Subcohort (n¼ 176) Nondiabetic Individuals (n¼ 86) Diabetic Individuals (n¼ 90)
A. Demographics N (%) Mean (range) N (%) Mean (range) N (%) Mean (range)
Sex
Female 133 (75.6) — 65 (75.6) — 68 (75.6) —
Male 43 (24.4) — 21 (24.4) — 22 (24.4) —
Age (years) — 50 (18–79) — 50 (18–78) — 51 (23–79)
BMI — 30.4 (18.3–45.2) — 30.1 (19.2–43.6) — 30.7 (18.3–45.2)
Fasting blood glucose — 131.1 (49.5–379.0) — 88.7 (49.0.5–117)* — 169.7(63.0–379.0)*
2HPG — 163.8(50.0–437.0) — 112.5(50.0–191.5)* — 211.1 (50.5–437.0)*
B. Arsenic exposure
DW-iAs (mg/l) — 68.4 (LOD–292.9) 65.8 (LOD–284.7) 70.8 (LOD–284.7)
 10 mg/l 20 (11.3) — 11 (12.8) — 9 (10.0) —
 10 mg/l 156 (88.7) — 75 (87.2) — 81 (90.0) —
 25 mg/l 24 (13.1) — 14 (16.3) — 10 (11.1) —
 25 mg/l 152 (86.9) — 72 (83.7) — 80 (89.9) —
U-tAsa — 86.8 (3.85–348.6) — 80.5 (6.11–348.61) — 92.6 (3.85–346.3)
aSum of iAs, MMAs, DMAs.
*Statistically significant difference between diabetic and nondiabetic groups.








Overall 103 32 132
Increased metabolite level 68 (66) 9 (31) 77
Decreased metabolite level 35 (34) 20 (68) 55
Nondiabetic individuals 61 15 73
Increased metabolite level 35 (57) 3 (20) 36
Decreased metabolite level 26 (43) 12 (80) 37
Diabetic individuals 73 17 87
Increased metabolite level 52 (71) 9 (53) 59
Decreased metabolite level 21 (29) 8 (47) 28
aTotal number of urinary metabolites tested n¼294.
bTotal number of plasma metabolites tested n¼ 221.
Numbers in bold represent total numbers of U-tAs associated metabolites.
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individuals, a single pathway was enriched, namely the pathway
for biosynthesis of phenylalanine, tyrosine, and tryptophan (Fig.
1d, Table 3). The 17 plasma metabolites associated with U-tAs in
diabetic individuals enriched for 8 pathways (Fig. 1d, Table 3). Of
these 8, 5 are associated with amino acid metabolism (arginine/
proline, lysine, phenylanine, and tyrosine and aminoacyl-tRNA
biosynthesis), 2 are associated with energy metabolism (nitrogen
metabolism and TCA cycle), and 1 pathway is associated with thi-
amine metabolism (Table 3). An examination of the overlap
between the study groups at a pathway level revealed that there
were no pathways associated with U-tAs in both nondiabetic and
diabetic subjects (Fig. 1d, Supplementary Table 2). Specifically,
there was 1 pathway unique to the response of nondiabetic sub-
jects to arsenic exposure, and 8 pathways unique to the diabetic
response to iAs exposure.
As a separate analysis, the 59 metabolites that were
uniquely associated with U-tAs in diabetic individuals (i.e. 42
urinary metabolites and 17 plasma metabolites) were also
assessed for their enriched metabolic pathways, a total of 10
metabolic pathways were identified (Table 3). Among these,
were 5 pathways related to amino acid metabolism, 3 related to
energy metabolism and 2 related to B vitamin (biotin, riboflavin,
and thiamine) metabolism.
DISCUSSION
A consensus exists that moderate-to-high chronic exposures to
iAs are associated with an increased risk of diabetes (Maull
et al., 2012). However, questions remain about pathophysiologi-
cal processes that underlie this disease and about the pheno-
type of diabetes developed in the presence of iAs exposure. One
way to address these questions is the identification of metabolic
shifts associated with iAs exposure among diabetic and
nondiabetic individuals. Here we examined plasma and urine
metabolites that were altered in response to iAs exposure in
both nondiabetic and diabetic individuals in our Chihuahua
cohort where the association between iAs exposure and preva-
lent diabetes was recently established (Currier et al., 2014).
These metabolites and their corresponding pathways were then
compared to identify features that were common or unique to
the nondiabetic and diabetic individuals in their response to iAs
exposure, to gain insight into iAs-associated disease.
We identified a total of 132 urinary and plasma metabolites
that were associated with U-tAs in either nondiabetic or dia-
betic individuals, with 103 urinary metabolites and 32 plasma
metabolites. Approximately, one-third of the urinary metabo-
lites that were U-tAs associated (31/103, 30%) were identified as
common to both nondiabetic and diabetic subjects. It was inter-
esting to note that in contrast to urine, no overlap was observed
in plasma, highlighting the nonconcordant results in the matri-
ces measured. The 31 urinary metabolites that were common
between the nondiabetic and diabetic individuals include but
are not limited to metabolites that broadly play a role in amino
acid metabolism (aspartic acid), the TCA cycle (malate, cAMP)
and pyruvate metabolism (acetylphosphate). It is important to
note that all of these metabolites were changed similarly in
their levels between nondiabetic and diabetic subjects demon-
strating a broad, disease-independent response to iAs exposure.
As these pathways are critical for energy processing, including
adenosine triphosphate (ATP) production (Dashty, 2013), altera-
tions of these pathways could indicate impacts of iAs exposure
on cellular energy production. In addition, the data suggest that
effects of iAs exposure within the shared pathways may differ
between diabetic and nondiabetic subjects. For example, the
effects on TCA cycle in diabetics included shifts in succinate
and fumarate, whereas isocitrate and oxaloacetate were shifted
FIG. 1. U-tAs associated urinary and plasma metabolites and pathways identified for diabetic and nondiabetic individuals. Venn diagrams illustrate the overlap of
metabolites in urine (a) or plasma (b) and of pathways in urine (c) or plasma (d) between nondiabetic individuals and diabetic individuals.
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TABLE 3. Pathways Enriched for U-tAs Associated Metabolites in Plasma and Urine of Diabetic and Nondiabetic Individuals
Class of
Metabolism
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only among nondiabetics; shifts in the concentrations of
another two TCA cycle metabolites, aconitic acid and malate,
were shared by both conditions. It is known that trivalent iAs, at
high doses, can inhibit pyruvate dehydrogenase by binding
directly (Hughes, 2002). This mode of action has also been sug-
gested to decrease ATP production.
In the context of disease specificity, we identified a set of 59
U-tAs-associated metabolites that were unique to the diabetic
individuals, specifically 42 U-tAs-associated urinary metabolites
and 17 U-tAs-associated plasma metabolites. Among these
diabetes-specific metabolites were those that play a role in two
major areas of human metabolism: (1) the TCA cycle and energy-
related pathways (succinate, furmarate, taurine) and (2) amino
acid metabolism (glycine, serine, methionine, lysine, proline,
5-aminolevulinic acid, glutaric acid, carnitine, tyrosine, and phe-
nylglyoxylic acid). Within this group of metabolites are also those
associated with metabolism of three major B vitamins: biotin,
riboflavin, and thiamine. Notably, these vitamins are known for
their roles in both the energy and the amino acid metabolism.
Additionally, both deficiencies for riboflavin and thiamine have
been shown to be associated with increased incidence of skin
lesions in human populations (Melkonian et al., 2012). Also,
methionine and thiamine, in conjunction with other
antioxidants, have been shown to reverse the oxidative stress
burden in target organs of mice exposed to arsenic (Nandi et al.,
2005).
Although diabetes developed in the presence of chronic
exposure to iAs has been often referred to as Type-2 diabetes,
an exact disease phenotype is only poorly characterized. When
we compared the 59 U-tAs-associated metabolites unique to
diabetic individuals in the Chihuahua cohort with the previ-
ously published Type 2 diabetes-associated metabolites (Kaur
et al., 2013; Wang et al., 2011) or metabolites that predict the risk
of Type 2 diabetes (Kaur et al., 2013), we found only 4 shared
metabolites: tyrosine, taurine, succinate, 3-hydroxy-3-methyl-
glutaric acid even though 14 metabolites were common across
all studies. Thus, most of the metabolites that shifted in the
urine or plasma of diabetic individuals in response to iAs expo-
sure were not among the Type 2 diabetes-associated metabo-
lites reported in previous studies. These results point to a
unique phenotype of iAs-associated diabetes apparent at the
level of the metabolome. It is possible that the U-tAs-associated
metabolites unique to diabetic individuals represent a metabo-
lomic fingerprint of iAs-associated diabetes.
Although a metabolomics phenotype of iAs-associated dia-
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* n represents the total number of U-tAs associated metabolites.
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Most importantly, it was not possible to establish whether dia-
betic individuals’ metabolomics differences were due to diabe-
tes developing as a result of iAs exposure or if diabetic
individuals respond differently to iAs. The response of an indi-
vidual to environmental exposures is multifactorial. For this
reason, the analysis performed controlled for factors known to
influence disease such as age, BMI, and gender. As with similar
study designs, it is not possible to assess the roles played by
genetic susceptibility, diet, and other lifestyle factors. Another
limitation of this study was that U-tAs was not strongly corre-
lated to DW-iAs suggesting the potential for additional sources
of As exposure, such as diet and occupational exposures. In
addition, it is not possible to directly compare the metabolomes
between diabetic and nondiabetic individuals as they were
matched on levels of iAs exposure. Further investigations,
including both population-based and laboratory models, are
necessary to determine perturbation of these metabolites is a
potential mechanism by which iAs influences diabetes status.
Taken together there are three major findings from this
study: first, we have identified more than 100 metabolites that
are altered in urine and plasma in response to iAs exposure.
Second a set of these metabolites was identified that differenti-
ates diabetic individuals from nondiabetic individuals. Third,
only a minimal overlap was observed between previously iden-
tified Type 2 diabetes-associated metabolites and the diabetes-
specific iAs exposure-associated metabolites, representing a
putative fingerprint of iAs-associated diabetes. These data pro-
vide insight into the complex mechanism of action of iAs-asso-
ciated disease in human populations with relevance to millions
around the globe.
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